Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Longeveron Inc LGVN

Healthcare Biotechnology
Longeveron Inc. is a clinical-stage biotechnology company. The Company is focused on developing cellular therapies for specific aging-related and life-threatening conditions. The Company's lead investigational product is the LOMECEL-B cell-based therapy product (Lomecel-B), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young healthy adult donors. The Company is primarily focused on three pipeline indications, which include Hypoplastic Left Heart Syndrome (HLHS), Alzheimer’s disease (AD) and Aging-related Frailty. Its Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti- inflammatory, and tissue repair and healing effects with potential applications across a spectrum of disease areas. The Company has bone marrow supply contracts in with two suppliers: the Oklahoma Blood Institute and Vista Health Research.


NDAQ:LGVN - Post by User

Longeveron Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Post by PressReleaseon Apr 15, 2024 8:30am
11 Views
Post# 35988950

New Press Release - Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B(TM) in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)

New Press Release - Longeveron's CLEAR MIND Randomized Phase 2a Clinical Trial Evaluating Lomecel-B(TM) in Mild Alzheimer's Disease Accepted for Featured Research Session Oral Presentation at the 2024 Alzheimer's Association International Conference (AAIC)
MIAMI, April 15, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it has been accepted for a Featured Research Oral Presentation to present the Company’s CLEAR MIND Phase 2a study results. CLEAR...read article.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities